BioAge Q2 FY26 net loss widens to $26.1 million; R&D expenses rise to $24.37 million
Reuters2026/08/05 20:56- BioAge Labs posted a Q2 net loss of $26.1 million, worsening from $21.6 million a year earlier.
- R&D expenses rose to $24.4 million, up from $19.8 million, on higher BGE-102 costs tied to QUELL-CV initiation.
- Collaboration revenue was $2.4 million, in line with the year-earlier quarter.
- Cash, cash equivalents, marketable securities totaled $381.3 million as of June 30, with runway expected through 2029.
- First participant was dosed in QUELL-CV Phase 2; topline data are expected in H2 2026, with QUELL-DME planned mid-2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Port of Tauranga wins fast-track approval for Stella Passage development
Crypto prices
More
